Figure 2.

FAK expression and patient characteristics in MDS. A, FAK levels determined by RPPA in CD34⁺ and CD34⁺CD38⁻ cells from newly diagnosed MDS patient samples and CD34⁺ cells from normal controls. B, FAK levels in CD34⁺ cells from newly diagnosed MDS patient samples determined by RPPA and patients’ OS. C, comparisons of FAK levels between MDS patients not transformed and later transformed to AML and between de novo and MDS transformed AML patients (Statistica, Version 12).